Jacob Bor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacob Bor has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
- Matthew P. Fox
Departments of Epidemiology and Global Health Boston University School of Public Health Boston Massachusetts USA
11 shared publications Till Bärnighausen
Africa Health Research Institute, KwaZulu-Natal, South Africa
8 shared publications- Sydney Rosen
Boston University School of Public Health
7 shared publications - William Bruce MacLeod
Department of Global Health, Boston University School of Public Health
7 shared publications - Andrew C. Stokes
Department of Global Health, Boston University School of Public Health, Boston, MA, USA
6 shared publications Dorina Onoya
Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
6 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in The Lancet HIV
- Vol. 13 (8) , e548-e556
Durability of HIV viral suppression in South Africa: a national cohort study
- 29 July 2026
- Published by Elsevier in The Lancet HIV
- Vol. 13 (8) , e548-e556
Open AccessDurability of HIV viral suppression in South Africa: a national cohort study
- Open Access
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e266147
Causes of Excess Deaths in the US Compared With Other High-Income Countries
Importance: The US has higher mortality rates than other high-income countries (HICs). However, a comprehensive analysis of excess US deaths encompassing all leading causes of death over the past 2 decades is currently lacking. Objective: To investigate causes of death responsible for excess US mortality compared with other HICs and how the causes of death involved in this US mortality disadvantage have changed over time. Design, Setting, and Participants: This repeated cross-sectional study included mortality data from the World Health Organization Mortality Database spanning 1999 to 2022 for the US and 17 other HICs. Data were analyzed from September 2023 to December 2025. Exposures: Residing in the US vs another of the included HICs. Main Outcome and Measures: The main outcome was excess US mortality in each year due to specific causes of death. Differences between the US and other HICs were quantified for each cause of death as (1) excess US deaths (ie, absolute difference between observed deaths and deaths expected if US death rates equaled the rates of other HICs); (2) years of life lost (YLL) resulting from excess US deaths; and (3) mortality rate ratios (ie, ratios of observed to expected age-standardized death rates). Results: A total of 63 547 318 deaths occurred in the US from 1999 to 2022 (50.4% among males; mean [SD] age at death, 73.2 [18.5] years). In this period, 12 675 646 excess US deaths occurred, increasing from 346 166 in 1999 to 905 159 in 2022. Circulatory diseases were the leading cause of excess US deaths every year except 2010, increasing after 2001 for ages 45 to 64 years and after 2009 for ages 65 years or older. Together, circulatory and metabolic diseases accounted for 52% of excess US deaths in 2022. Excess US deaths due to drug poisonings, alcohol, and suicide increased from −5762 in 1999 to 131 151 in 2022; together, these 3 causes accounted for 24% of the increase in excess US deaths overall and most of the increase in excess US deaths for individuals aged 0 to 44 years. In 2022, deaths from drug poisonings were 7.48 times higher in the US than in other HICs. In 2020 and 2021, 19% and 23% of excess US deaths, respectively, were attributed to COVID-19, but excess US deaths from other causes also increased. Conclusions and Relevance: In this repeated cross-sectional study of cross-national mortality, the US had substantially higher death rates than other HICs between 1999 and 2022, despite having similar access to advanced medical technology. Many of these excess US deaths could likely be avoided by adopting health and social policies that have benefited other HICs. These descriptive findings should be interpreted in light of uncertainty arising from differences in death coding, data completeness, and other aspects of data comparability across countries.
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e266147
Open AccessCauses of Excess Deaths in the US Compared With Other High-Income Countries
Importance: The US has higher mortality rates than other high-income countries (HICs). However, a comprehensive analysis of excess US deaths encompassing all leading causes of death over the past 2 decades is currently lacking. Objective: To investigate causes of death responsible for excess US mortality compared with other HICs and how the causes of death involved in this US mortality disadvantage have changed over time. Design, Setting, and Participants: This repeated cross-sectional study included mortality data from the World Health Organization Mortality Database spanning 1999 to 2022 for the US and 17 other HICs. Data were analyzed from September 2023 to December 2025. Exposures: Residing in the US vs another of the included HICs. Main Outcome and Measures: The main outcome was excess US mortality in each year due to specific causes of death. Differences between the US and other HICs were quantified for each cause of death as (1) excess US deaths (ie, absolute difference between observed deaths and deaths expected if US death rates equaled the rates of other HICs); (2) years of life lost (YLL) resulting from excess US deaths; and (3) mortality rate ratios (ie, ratios of observed to expected age-standardized death rates). Results: A total of 63 547 318 deaths occurred in the US from 1999 to 2022 (50.4% among males; mean [SD] age at death, 73.2 [18.5] years). In this period, 12 675 646 excess US deaths occurred, increasing from 346 166 in 1999 to 905 159 in 2022. Circulatory diseases were the leading cause of excess US deaths every year except 2010, increasing after 2001 for ages 45 to 64 years and after 2009 for ages 65 years or older. Together, circulatory and metabolic diseases accounted for 52% of excess US deaths in 2022. Excess US deaths due to drug poisonings, alcohol, and suicide increased from −5762 in 1999 to 131 151 in 2022; together, these 3 causes accounted for 24% of the increase in excess US deaths overall and most of the increase in excess US deaths for individuals aged 0 to 44 years. In 2022, deaths from drug poisonings were 7.48 times higher in the US than in other HICs. In 2020 and 2021, 19% and 23% of excess US deaths, respectively, were attributed to COVID-19, but excess US deaths from other causes also increased. Conclusions and Relevance: In this repeated cross-sectional study of cross-national mortality, the US had substantially higher death rates than other HICs between 1999 and 2022, despite having similar access to advanced medical technology. Many of these excess US deaths could likely be avoided by adopting health and social policies that have benefited other HICs. These descriptive findings should be interpreted in light of uncertainty arising from differences in death coding, data completeness, and other aspects of data comparability across countries.
- Open Access
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials
Background: Clinical trials evaluating the impact of switching to dolutegravir have excluded individuals with poorly controlled viremia. However, in practice, clinicians may switch individuals to dolutegravir who have such challenges. Utilizing the Target Trial Framework, we estimated the effect of switching to a dolutegravir-based regimen, vs not switching and remaining on an efavirenz-based regimen, on 12- and 24-month retention and viral suppression in Johannesburg, South Africa, from 2019 to 2022. Methods: Using data from the Themba Lethu HIV Clinical Cohort, individuals were eligible if they were currently on an efavirenz-based regimen, aged 16+, and not pregnant at the start of each trial. We conducted a pooled linear regression model with bootstrapping to estimate the causal risk difference and 95% CI adjusting for patient characteristics via inverse probability treatment weighting. Results: Of 1493 individuals, 967 (64.7%) switched to a dolutegravir-based regimen over 9 sequential trials, and 526 (35.2%) did not. At 12 months, switch to a dolutegravir-based regimen was associated with a 14 percentage point (95% CI, 0.10 to 0.19) increase in retention and a 2 percentage point (95% CI, −0.04 to 0.08) increase in viral suppression. By 24 months, we observed a 1 percentage point (95% CI, −0.05 to 0.07) increase in retention and an 8 percentage point (95% CI, 0.02 to 0.14) increase in viral suppression. Conclusions: Switching to dolutegravir was associated with a 14 percentage point increase in retention at 12 months and an 8 percentage point increase in viral suppression at 24 months. Our findings suggest that switching to dolutegravir does not harm and might improve retention and viral suppression over a 24-month period.
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Open AccessOne- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials
Background: Clinical trials evaluating the impact of switching to dolutegravir have excluded individuals with poorly controlled viremia. However, in practice, clinicians may switch individuals to dolutegravir who have such challenges. Utilizing the Target Trial Framework, we estimated the effect of switching to a dolutegravir-based regimen, vs not switching and remaining on an efavirenz-based regimen, on 12- and 24-month retention and viral suppression in Johannesburg, South Africa, from 2019 to 2022. Methods: Using data from the Themba Lethu HIV Clinical Cohort, individuals were eligible if they were currently on an efavirenz-based regimen, aged 16+, and not pregnant at the start of each trial. We conducted a pooled linear regression model with bootstrapping to estimate the causal risk difference and 95% CI adjusting for patient characteristics via inverse probability treatment weighting. Results: Of 1493 individuals, 967 (64.7%) switched to a dolutegravir-based regimen over 9 sequential trials, and 526 (35.2%) did not. At 12 months, switch to a dolutegravir-based regimen was associated with a 14 percentage point (95% CI, 0.10 to 0.19) increase in retention and a 2 percentage point (95% CI, −0.04 to 0.08) increase in viral suppression. By 24 months, we observed a 1 percentage point (95% CI, −0.05 to 0.07) increase in retention and an 8 percentage point (95% CI, 0.02 to 0.14) increase in viral suppression. Conclusions: Switching to dolutegravir was associated with a 14 percentage point increase in retention at 12 months and an 8 percentage point increase in viral suppression at 24 months. Our findings suggest that switching to dolutegravir does not harm and might improve retention and viral suppression over a 24-month period.
- Open Access
- 27 April 2026
- Published by BMJ in BMJ Global Health
- Vol. 11 (4) , e021929
Postpartum continuity of care for women with HIV: Option B+ policy impact and limitations in South Africa
Introduction: Postpartum disengagement from HIV care increases risks for adverse maternal health outcomes and transmission of HIV through breastfeeding. In January 2015, South Africa implemented Option B+, a policy extending lifelong antiretroviral therapy (ART) eligibility to all pregnant women living with HIV (PWLWH) regardless of CD4 count. We assessed the impact of Option B+ on postpartum retention in HIV care for PWLWH and identified predictors of disengagement in the Option B+ era. Methods: We linked maternal data from Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa, to HIV laboratory records from the National Health Laboratory Service. Using quasi-experimental designs (differences-in-differences; regression discontinuity), we estimated the causal effect of Option B+ on postpartum retention in HIV care, defined as any HIV-related laboratory test result 6–24 months after delivery. PWLWH with CD4>500 cells/µL were newly eligible for lifelong ART under Option B+ (‘treatment’ group); PWLWH with CD4≤350 cells/µL served as ‘controls’ as their eligibility for lifelong ART was unchanged by the policy. We also assessed predictors of postpartum disengagement from care in the Option B+ era using logistic regression models. Results: We included 1684 women delivering from 1 July 2013 to 30 June 2016, of which 14% delivered in the pre-Option B+ period. Option B+ was associated with a 19 percentage point increase (95% CI 6% to 33%) in postpartum retention for the treatment group, relative to controls. We observed a 29 percentage point increase (95% CI 7% to 52%) in retention in the treatment group immediately after policy implementation. In the Option B+ era, PWLWH who initiated ART during pregnancy had 76% lower odds of postpartum retention than those who were already on ART before their pregnancy (OR: 0.24, 95% CI 0.18 to 0.32). Conclusion: Option B+ improved postpartum retention among PWLWH newly eligible for lifelong ART. Still, women initiating ART during pregnancy exhibited significantly lower retention than those already on treatment, highlighting the need for further support to sustain care in this group.
- 27 April 2026
- Published by BMJ in BMJ Global Health
- Vol. 11 (4) , e021929
Open AccessPostpartum continuity of care for women with HIV: Option B+ policy impact and limitations in South Africa
Introduction: Postpartum disengagement from HIV care increases risks for adverse maternal health outcomes and transmission of HIV through breastfeeding. In January 2015, South Africa implemented Option B+, a policy extending lifelong antiretroviral therapy (ART) eligibility to all pregnant women living with HIV (PWLWH) regardless of CD4 count. We assessed the impact of Option B+ on postpartum retention in HIV care for PWLWH and identified predictors of disengagement in the Option B+ era. Methods: We linked maternal data from Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa, to HIV laboratory records from the National Health Laboratory Service. Using quasi-experimental designs (differences-in-differences; regression discontinuity), we estimated the causal effect of Option B+ on postpartum retention in HIV care, defined as any HIV-related laboratory test result 6–24 months after delivery. PWLWH with CD4>500 cells/µL were newly eligible for lifelong ART under Option B+ (‘treatment’ group); PWLWH with CD4≤350 cells/µL served as ‘controls’ as their eligibility for lifelong ART was unchanged by the policy. We also assessed predictors of postpartum disengagement from care in the Option B+ era using logistic regression models. Results: We included 1684 women delivering from 1 July 2013 to 30 June 2016, of which 14% delivered in the pre-Option B+ period. Option B+ was associated with a 19 percentage point increase (95% CI 6% to 33%) in postpartum retention for the treatment group, relative to controls. We observed a 29 percentage point increase (95% CI 7% to 52%) in retention in the treatment group immediately after policy implementation. In the Option B+ era, PWLWH who initiated ART during pregnancy had 76% lower odds of postpartum retention than those who were already on ART before their pregnancy (OR: 0.24, 95% CI 0.18 to 0.32). Conclusion: Option B+ improved postpartum retention among PWLWH newly eligible for lifelong ART. Still, women initiating ART during pregnancy exhibited significantly lower retention than those already on treatment, highlighting the need for further support to sustain care in this group.
- Open Access
- 1 March 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (3) , 316-324
Timing of ART Initiation With Treatment Policy Changes in South Africa: A Cohort Study
Background: Early antiretroviral therapy (ART) improves uptake, retention, and viral suppression. However, there is limited real-world data for high HIV burden settings, including South Africa. Methods: We conducted a retrospective cohort study using linked clinical CD4 and viral load (VL) data from South Africa's HIV treatment database (TIER.Net) and National Health Laboratory Service (NHLS). Our analysis included ART non-naive individuals entering HIV care between January 2010 and March 2017 in 4 provinces (KwaZulu-Natal, Northern Cape, Limpopo, and Mpumalanga). We estimated days from entry into HIV care (same day, 2–6 days, 7–89 days, and ≥90 days). Outcome measures included retention, viral suppression (VL <50 copies/mL), and CD4 recovery at 12 months. A Poisson regression model with adjusted Risk Ratios (aRR) was used to identify factors associated with rapid ART initiation (<7 days) at 5% significance level. Results: Among 1,211,966 individuals (median age 31 years, 69.6% female), 30% initiated ART on the day of diagnosis, 4.2% within 2–6 days, 26% within 7–89 days, and 39.8% after ≥90 days. Rapid ART initiation increased over time, with same-day initiations rising from 24.6% in 2010 to 60% in 2017. Factors associated with rapid ART initiation included female gender (aRR: 1.04; 95% CI: 1.03 to 1.04) and a lower CD4 count at entry. At 12 months, 77.6% of same-day initiators were retained, with 28.4% having a VL test and 61.2% achieving viral suppression. Conclusions: Rapid ART initiation has increased because of policy changes and healthcare worker efforts in South Africa, but addressing late entry into care and treatment nonadherence remains crucial.
- 1 March 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (3) , 316-324
Open AccessTiming of ART Initiation With Treatment Policy Changes in South Africa: A Cohort Study
Background: Early antiretroviral therapy (ART) improves uptake, retention, and viral suppression. However, there is limited real-world data for high HIV burden settings, including South Africa. Methods: We conducted a retrospective cohort study using linked clinical CD4 and viral load (VL) data from South Africa's HIV treatment database (TIER.Net) and National Health Laboratory Service (NHLS). Our analysis included ART non-naive individuals entering HIV care between January 2010 and March 2017 in 4 provinces (KwaZulu-Natal, Northern Cape, Limpopo, and Mpumalanga). We estimated days from entry into HIV care (same day, 2–6 days, 7–89 days, and ≥90 days). Outcome measures included retention, viral suppression (VL <50 copies/mL), and CD4 recovery at 12 months. A Poisson regression model with adjusted Risk Ratios (aRR) was used to identify factors associated with rapid ART initiation (<7 days) at 5% significance level. Results: Among 1,211,966 individuals (median age 31 years, 69.6% female), 30% initiated ART on the day of diagnosis, 4.2% within 2–6 days, 26% within 7–89 days, and 39.8% after ≥90 days. Rapid ART initiation increased over time, with same-day initiations rising from 24.6% in 2010 to 60% in 2017. Factors associated with rapid ART initiation included female gender (aRR: 1.04; 95% CI: 1.03 to 1.04) and a lower CD4 count at entry. At 12 months, 77.6% of same-day initiators were retained, with 28.4% having a VL test and 61.2% achieving viral suppression. Conclusions: Rapid ART initiation has increased because of policy changes and healthcare worker efforts in South Africa, but addressing late entry into care and treatment nonadherence remains crucial.
- Open Access
- 18 December 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (12) , e70069
A call to action to advance global research priorities related to Undetectable = Untransmittable
Introduction: The Undetectable = Untransmittable (U = U) message has failed to reach many people living with HIV (PLHIV) and their communities despite evidence of its favourable impacts. Discussion: We describe and contextualize six global research priorities related to U = U, which focus on: (1) examining the effects of U = U messaging on health and economic outcomes; (2) illuminating and addressing barriers to U = U communication among healthcare providers, policymakers and other stakeholders; (3) expanding U = U research to include all key populations disproportionately affected by HIV; (4) addressing limited and inequitable access to information and resources; (5) determining how to optimally communicate about U = U in the context of evolving scientific knowledge and guidelines; and (6) collaborating on parallel studies across countries to improve comparability of study findings and identify cross‐cultural differences. Conclusions: Future research targeting these six priorities is needed to guide effective messaging about U = U in healthcare settings and public health programmes throughout the world. Ultimately, bridging existing gaps in U = U awareness, understanding and acceptance can enable PLHIV and others to reap the benefits associated with this valuable message.
- 18 December 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (12) , e70069
Open AccessA call to action to advance global research priorities related to Undetectable = Untransmittable
Introduction: The Undetectable = Untransmittable (U = U) message has failed to reach many people living with HIV (PLHIV) and their communities despite evidence of its favourable impacts. Discussion: We describe and contextualize six global research priorities related to U = U, which focus on: (1) examining the effects of U = U messaging on health and economic outcomes; (2) illuminating and addressing barriers to U = U communication among healthcare providers, policymakers and other stakeholders; (3) expanding U = U research to include all key populations disproportionately affected by HIV; (4) addressing limited and inequitable access to information and resources; (5) determining how to optimally communicate about U = U in the context of evolving scientific knowledge and guidelines; and (6) collaborating on parallel studies across countries to improve comparability of study findings and identify cross‐cultural differences. Conclusions: Future research targeting these six priorities is needed to guide effective messaging about U = U in healthcare settings and public health programmes throughout the world. Ultimately, bridging existing gaps in U = U awareness, understanding and acceptance can enable PLHIV and others to reap the benefits associated with this valuable message.
- Open Access
Gaps in the Type 1 Diabetes Mellitus care cascade: a national perspective using South Africa’s National Health Laboratory Service (NHLS) database
Objective: Type 1 diabetes mellitus (T1DM) requires lifelong management, yet access to insulin, specialized care, and education is limited in low- and middle-income countries (LMICs). While cascade-of-care analyses are well documented for type 2 diabetes (T2DM), to our knowledge no population-level estimates of the T1DM care cascade exist from LMICs. We therefore evaluated the T1DM care cascade nationally in South Africa and compared outcomes between youth living with HIV (YLWH) and youth living without HIV (YLWOH). Research Design and Methods: We analyzed South Africa’s National Health Laboratory Service (NHLS) data for patients <20 years with a first glycated hemoglobin A1c (HbA1c) or plasma glucose [fasting (FPG), random (RPG)] between April 2004 and March 2015. Laboratory-diagnosed T1DM was defined as HbA1c ≥6.5%, FPG ≥7.0 mmol/L, or RPG ≥11.1 mmol/L. Cascade stages over 24 months were remaining in care and achieving glycemic control (HbA1c <7.0%, FPG <8.0 mmol/L, or RPG <10.0 mmol/L). Results: Of 256,449 youth tested for diabetes, 12.1% met criteria for laboratory-diagnosed T1DM. Among these, 15.9% remained in care and 7.2% achieved glycemic control by 24 months. Retention was similar between YLWH and YLWOH (16.8% vs. 15.8%), but glycemic control was higher among YLWH (72.5% vs. 43.4%). Conclusions: Four of five South African youth with T1DM lacked consistent care, and fewer than 10% achieved glycemic control within two years. Higher control rates among YLWH suggest lessons from HIV care models may strengthen T1DM services. These findings provide the first national estimates of the T1DM care cascade from sub-Saharan Africa and highlight the urgent need for targeted strategies to improve outcomes.
Open AccessGaps in the Type 1 Diabetes Mellitus care cascade: a national perspective using South Africa’s National Health Laboratory Service (NHLS) database
Objective: Type 1 diabetes mellitus (T1DM) requires lifelong management, yet access to insulin, specialized care, and education is limited in low- and middle-income countries (LMICs). While cascade-of-care analyses are well documented for type 2 diabetes (T2DM), to our knowledge no population-level estimates of the T1DM care cascade exist from LMICs. We therefore evaluated the T1DM care cascade nationally in South Africa and compared outcomes between youth living with HIV (YLWH) and youth living without HIV (YLWOH). Research Design and Methods: We analyzed South Africa’s National Health Laboratory Service (NHLS) data for patients <20 years with a first glycated hemoglobin A1c (HbA1c) or plasma glucose [fasting (FPG), random (RPG)] between April 2004 and March 2015. Laboratory-diagnosed T1DM was defined as HbA1c ≥6.5%, FPG ≥7.0 mmol/L, or RPG ≥11.1 mmol/L. Cascade stages over 24 months were remaining in care and achieving glycemic control (HbA1c <7.0%, FPG <8.0 mmol/L, or RPG <10.0 mmol/L). Results: Of 256,449 youth tested for diabetes, 12.1% met criteria for laboratory-diagnosed T1DM. Among these, 15.9% remained in care and 7.2% achieved glycemic control by 24 months. Retention was similar between YLWH and YLWOH (16.8% vs. 15.8%), but glycemic control was higher among YLWH (72.5% vs. 43.4%). Conclusions: Four of five South African youth with T1DM lacked consistent care, and fewer than 10% achieved glycemic control within two years. Higher control rates among YLWH suggest lessons from HIV care models may strengthen T1DM services. These findings provide the first national estimates of the T1DM care cascade from sub-Saharan Africa and highlight the urgent need for targeted strategies to improve outcomes.
- Open Access
Postpartum continuity of care for women with HIV: Option B+ policy impact and limitations in South Africa
Introduction: Postpartum disengagement from HIV care is high, leading to adverse maternal outcomes and risk of transmission through breastfeeding. In January 2015, South Africa implemented Option B+, a policy extending lifelong antiretroviral therapy (ART) eligibility to all pregnant women living with HIV (PWLWH) regardless of CD4 count. We assessed the impact of Option B+ on postpartum continuity of care for PWLWH and identified predictors of disengagement in the Option B+ era. Methods: We linked maternal data from Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa, to HIV laboratory records from the National Health Laboratory Service. Using quasi-experimental designs (difference-in-differences, DID; regression-discontinuity, RD), we estimated the causal effect of Option B+ on postpartum retention in HIV care, defined as any HIV lab result 6-24 months after delivery. PWLWH with CD4 >500 cells/μL were newly eligible for lifelong ART under Option B+ (“treatment” group); PWLWH with CD4 ≤350 cells/μL served as “controls” as their eligibility for lifelong ART was unchanged by the policy. We also assessed predictors of postpartum disengagement from care in the Option B+ era. Results: We included 1,684 women delivering 01/07/2013–30/06/2016, of which 14% delivered in the pre-Option B+ period. Option B+ was associated with a 19% increase (95% CI: 6%–33%) in postpartum retention for treatment group, relative to controls. We observed a 29% jump (95% CI: 7%–52%) in retention at the policy threshold in the treatment group. In the Option B+ era, PWLWH initiating ART during pregnancy had 76% lower odds of retention than those already on ART (OR: 0.24, 95% CI: 0.18–0.32). Conclusion: Option B+ improved retention among PWLWH newly eligible for lifelong ART. Still, despite lifelong ART eligibility, women initiating ART during pregnancy exhibited significantly lower retention than those already on treatment, highlighting the need for further support to sustain care in this group. Key messages: What is already known on this topic: Postpartum HIV care attrition is high among pregnant women living with HIV (PWLWH). The World Health Organization (WHO) published guidelines for preventing mother-to-child transmission of HIV, with Option B+ being the most recent guideline that extended lifelong ART eligibility to all PWLWH regardless of CD4 count. Existing research has reported suboptimal retention rates under Option B+, but has not specifically examined the impact on the population who gained eligibility under the new policy. What this study adds: This study examined postpartum HIV care retention among PWLWH with high CD4 counts – the group newly eligible for lifelong ART under Option B+. We used quasi-experimental methods to estimate the causal effect of Option B+ by comparing PWLWH who delivered just before vs. just after the Option B+ policy was implemented, and we explored drivers of postpartum attrition from care. We demonstrated that Option B+ significantly increased HIV care retention in PWLWH with high CD4 counts; but that further efforts will be needed to support retention in care among PWLWH starting ART during pregnancy. How this study might affect research, practice, and policy: Simplification of ART eligibility and expanded access to ART led to improvements in HIV care retention among PWLWH. However, PWLWH who initiated ART during pregnancy still experience high rates of attrition, highlighting the need for targeted interventions to support sustained care engagement for this group.
Open AccessPostpartum continuity of care for women with HIV: Option B+ policy impact and limitations in South Africa
Introduction: Postpartum disengagement from HIV care is high, leading to adverse maternal outcomes and risk of transmission through breastfeeding. In January 2015, South Africa implemented Option B+, a policy extending lifelong antiretroviral therapy (ART) eligibility to all pregnant women living with HIV (PWLWH) regardless of CD4 count. We assessed the impact of Option B+ on postpartum continuity of care for PWLWH and identified predictors of disengagement in the Option B+ era. Methods: We linked maternal data from Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa, to HIV laboratory records from the National Health Laboratory Service. Using quasi-experimental designs (difference-in-differences, DID; regression-discontinuity, RD), we estimated the causal effect of Option B+ on postpartum retention in HIV care, defined as any HIV lab result 6-24 months after delivery. PWLWH with CD4 >500 cells/μL were newly eligible for lifelong ART under Option B+ (“treatment” group); PWLWH with CD4 ≤350 cells/μL served as “controls” as their eligibility for lifelong ART was unchanged by the policy. We also assessed predictors of postpartum disengagement from care in the Option B+ era. Results: We included 1,684 women delivering 01/07/2013–30/06/2016, of which 14% delivered in the pre-Option B+ period. Option B+ was associated with a 19% increase (95% CI: 6%–33%) in postpartum retention for treatment group, relative to controls. We observed a 29% jump (95% CI: 7%–52%) in retention at the policy threshold in the treatment group. In the Option B+ era, PWLWH initiating ART during pregnancy had 76% lower odds of retention than those already on ART (OR: 0.24, 95% CI: 0.18–0.32). Conclusion: Option B+ improved retention among PWLWH newly eligible for lifelong ART. Still, despite lifelong ART eligibility, women initiating ART during pregnancy exhibited significantly lower retention than those already on treatment, highlighting the need for further support to sustain care in this group. Key messages: What is already known on this topic: Postpartum HIV care attrition is high among pregnant women living with HIV (PWLWH). The World Health Organization (WHO) published guidelines for preventing mother-to-child transmission of HIV, with Option B+ being the most recent guideline that extended lifelong ART eligibility to all PWLWH regardless of CD4 count. Existing research has reported suboptimal retention rates under Option B+, but has not specifically examined the impact on the population who gained eligibility under the new policy. What this study adds: This study examined postpartum HIV care retention among PWLWH with high CD4 counts – the group newly eligible for lifelong ART under Option B+. We used quasi-experimental methods to estimate the causal effect of Option B+ by comparing PWLWH who delivered just before vs. just after the Option B+ policy was implemented, and we explored drivers of postpartum attrition from care. We demonstrated that Option B+ significantly increased HIV care retention in PWLWH with high CD4 counts; but that further efforts will be needed to support retention in care among PWLWH starting ART during pregnancy. How this study might affect research, practice, and policy: Simplification of ART eligibility and expanded access to ART led to improvements in HIV care retention among PWLWH. However, PWLWH who initiated ART during pregnancy still experience high rates of attrition, highlighting the need for targeted interventions to support sustained care engagement for this group.
- Top Cited PapersOpen Access
- 2 May 2025
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 6 (5) , e251118
Excess US Deaths Before, During, and After the COVID-19 Pandemic
This cohort study examines trends in excess deaths in the US before, during, and after the COVID-19 pandemic.
- 2 May 2025
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 6 (5) , e251118
Top Cited PapersOpen AccessExcess US Deaths Before, During, and After the COVID-19 Pandemic
This cohort study examines trends in excess deaths in the US before, during, and after the COVID-19 pandemic.
- Open Access
- 5 September 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (9) , e0002127
The fall—And rise—In hospital-based care for people with HIV in South Africa: 2004–2017
ART scale-up has reduced HIV mortality in South Africa. However, less is known about trends in hospital-based HIV care, which is costly and may indicate HIV-related morbidity. We assessed trends in hospital-based HIV care using the National Health Laboratory Service (NHLS) National HIV Cohort. Our study included all adults ≥18 years receiving care in South Africa’s public sector HIV program from 2004 to 2017 with at least one CD4 count/viral load test in the NHLS database. We compared trends in the number of patients presenting for and receiving HIV care by facility type: hospitals vs. primary care clinics. We then assessed trends and predictors of incident hospitalization, defined as 2 or more hospital-based lab tests taken within 7 days. Finally, we assessed whether trends in incident hospitalizations could be explained by changes in patient demographics, CD4 counts, or facility type at presentation. Data were analyzed on 9,624,951 patients. The percentage of patients presenting and receiving HIV care at hospitals (vs. clinics) declined over time, from approximately 60% in 2004 to 15% in 2017. Risk of hospitalization declined for patients entering care between 2004–2012 and modestly increased for patients entering care after 2012. The risk of hospitalization declined the most in age groups most affected by HIV. Over time, patients presented with higher CD4 counts and were more likely to present at clinics, and these changes explained almost half the decline in hospitalizations. The percentage of HIV care provided in hospitals declined as patients presented in better health and as treatment was increasingly managed at clinics. However, there may still be opportunities to reduce incident hospitalizations in people with HIV.
- 5 September 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (9) , e0002127
Open AccessThe fall—And rise—In hospital-based care for people with HIV in South Africa: 2004–2017
ART scale-up has reduced HIV mortality in South Africa. However, less is known about trends in hospital-based HIV care, which is costly and may indicate HIV-related morbidity. We assessed trends in hospital-based HIV care using the National Health Laboratory Service (NHLS) National HIV Cohort. Our study included all adults ≥18 years receiving care in South Africa’s public sector HIV program from 2004 to 2017 with at least one CD4 count/viral load test in the NHLS database. We compared trends in the number of patients presenting for and receiving HIV care by facility type: hospitals vs. primary care clinics. We then assessed trends and predictors of incident hospitalization, defined as 2 or more hospital-based lab tests taken within 7 days. Finally, we assessed whether trends in incident hospitalizations could be explained by changes in patient demographics, CD4 counts, or facility type at presentation. Data were analyzed on 9,624,951 patients. The percentage of patients presenting and receiving HIV care at hospitals (vs. clinics) declined over time, from approximately 60% in 2004 to 15% in 2017. Risk of hospitalization declined for patients entering care between 2004–2012 and modestly increased for patients entering care after 2012. The risk of hospitalization declined the most in age groups most affected by HIV. Over time, patients presented with higher CD4 counts and were more likely to present at clinics, and these changes explained almost half the decline in hospitalizations. The percentage of HIV care provided in hospitals declined as patients presented in better health and as treatment was increasingly managed at clinics. However, there may still be opportunities to reduce incident hospitalizations in people with HIV.